30
total announcements
AARTIPHARM.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 16 Oct 2026
Market Cap
₹7,833 Cr
P/E (TTM)
36.8
P/E (Forward)
33.9
EPS (TTM)
₹23.50
52W Low
₹585.00
52W High
₹1,002.40
Dividend Yield
0.46%
Beta
0.26
Price / Book
3.7
Debt / Equity
37.4
Revenue (TTM)
₹1,969 Cr
Gross Margin
54.19%
Operating Margin
19.15%
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has filed a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on stock exchanges.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange about Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, regarding a writ petition filed by the company challenging an order levying stamp duty and penalties.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange regarding the reconstitution of its Board of Directors' committee.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange regarding the closure of the trading window due to SEBI (Prohibition of Insider Trading) Regulations, 2015, effective from October 1, 2026, until 48 hours after the declaration of financial results for the quarter ending September 30, 2026.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange regarding 'Updates on Change in Directorate'. The company has approved changes in the Directorate at the 7th Annual General Meeting (AGM) held on September 22, 2026. Shri Rajendra Gogri has ceased to be a Director, Smt. Hetal Gogri Gala has been re-designated as Whole-time Director, and Shri. Rashesh C. Gogri has been appointed as the Managing Director.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has submitted the Scrutinizer's report of the Annual General Meeting held on September 22, 2026, and informed the Exchange regarding voting results. All resolutions were passed with requisite majority.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange regarding 'Presentation made to the shareholders at 7th AGM'. The presentation highlights the company's 25+ years of pharmaceutical excellence, 220+ products, 500+ global clients, and 3 R&D facilities. It also discusses the company's growth journey, value creation, and standalone multi-year profitability metrics.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited held its 7th Annual General Meeting on September 22, 2026, where the shareholders approved the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and declared a final dividend of Rs.2/- per equity share. The meeting also saw the ratification of remuneration payable to cost auditors, change in designation of Hetal Gogri Gala, and appointment of Rashesh C. Gogri as Managing Director.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has received an order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat, pertaining to the adjudication of stamp duty on the Scheme of Arrangement (Demerger) between Aarti Industries Limited and Aarti Pharmalabs Limited. The order levies a stamp duty of Rs. 25 Crores and a penalty of Rs. 59,50,00,000. The company believes it has a strong case on merits and will challenge the order.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange about the cessation of Senior Management Personnel, Shri G.M. Naidu, Manufacturing/ Sr. General Manager, due to resignation, effective August 31, 2026.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange about publishing newspaper advertisements regarding dispatch to the Shareholders of Annual Report for the Financial Year 2025-26 and Notice of the 7th Annual General Meeting of the Company.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26, as required by SEBI regulations.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 22, 2026.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange about publishing newspaper advertisements for its 7th Annual General Meeting, fixing the record date for payment of final dividend for FY 2025-26, and requesting shareholders to register their Email-Ids with their depository participants.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has announced a record date of September 15, 2026, for the payment of a final dividend of 40% (₹2.00 per equity share) for the financial year 2025-26.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call held on 14th February, 2023.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has informed the Exchange about the link to the recording of their earnings conference call for the first quarter ended June 30, 2026, which can be accessed on their website.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has released its Q1 FY27 results presentation, highlighting its 25+ years of pharmaceutical excellence, 220+ products, 500+ global clients, and 63+ patents filed. The company has a strong presence in xanthine derivatives, CDMO/CMO services, and has received accreditations from USFDA, EU GMP, EDQM, and other agencies.
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited has published its unaudited financial results for the quarter ended June 30, 2026, in newspapers as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.